Mosby's 2014 Nursing Drug Reference (393 page)

BOOK: Mosby's 2014 Nursing Drug Reference
9Mb size Format: txt, pdf, ePub

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

ticagrelor

Brilinta

Func. class.:
Platelet inhibitor

Chem. class.:
ADP receptor antagonist

ACTION:

Reversibly bind to the platelet receptor, preventing platelet activation

USES:

Arterial thromboembolism prophylaxis in acute coronary syndrome (ACS) (unstable angina, acute MI), including in patients undergoing percutaneous coronary intervention (PCI)

CONTRAINDICATIONS:

Hypersensitivity, severe hepatic disease

 

Black Box Warning:

Bleeding, intracranial bleeding

Precautions:
Pregnancy (category C), breastfeeding, infants, neonates, children, GI bleeding, hepatic disease, abrupt discontinuation

 

Black Box Warning:

Coronary artery bypass graft surgery (CABG), surgery

DOSAGE AND ROUTES
Calculator

• Adult:
PO
loading dose 180 mg with aspirin (usually 325 mg PO); then, give 90 mg bid with aspirin 75-100 mg/day, do not give maintenance doses of aspirin >100 mg/day

Available forms:
Tab 90 mg

Administer:

• 
May be taken without regard to food

• 
Discontinue 5-7 days before surgery

• 
May be crushed (90 mg tab) and mixed with purified water, 100 mg (PO) or 50 ml (NG)

SIDE EFFECTS

CNS:
Headache, dizziness, fatigue

CV:
Hypertension, hypotension, chest pain, atrial fibrillation, bradyarrhythmias, syncope, ventricular pauses

GI:
Nausea, diarrhea

HEMA:
Serious, fatal bleeding

MISC:
Back pain, hyperuricemia, gynecomastia

RESP:
Dyspnea, cough

PHARMACOKINETICS

Absolute bioavailability 36%, protein binding (>99%), metabolism by CYP3A4, weak P-glycoprotein substrates and inhibitors, elimination for product and metabolite are hepatic and biliary, 84% excreted in feces, 26% in urine, half-life is 7 hr for ticagrelor, 9 hr for metabolite, maximum inhibition of platelet aggregation (IPA) effect 2 hr, maintained ≥8 hr, peak 1.5 hr product, 2.5 hr metabolite

INTERACTIONS

Increase:
bleeding risk—CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, lopinavir, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, delavirdine, isoniazid, dalfopristin, quinupristin, tipranavir

Decrease:
ticagrelor action—CYP3A4 inducers (rifampin, dexamethasone, phenytoin, carBAMazepine, PHENobarbital)

Increase:
effect of—simvastatin lovastatin

Increase:
bleeding risk—NSAIDs, anticoagulants, platelet inhibitors

Increase or decrease:
digoxin

Drug/Lab Test

Increase:
serum creatinine

NURSING CONSIDERATIONS
Assess:

• 
Thromboembolism:
Monitor CBC with differential with platelet count baseline and periodically during treatment

 

Black Box Warning:

Bleeding:
Assess for bleeding that may occur when aspirin is combined with this product, some bleeding can be fatal

• 
Abrupt discontinuation:
Do not discontinue abruptly, may increase risk for MI, stent thrombosis, death

Perform/provide:

• 
Storage at room temperature, in original container in dry place

Evaluate:

• 
Prevention of thromboembolism

Teach patient/family:

• 
To take only as prescribed, not to skip or double doses; if a dose is missed, to take next dose at scheduled time

 

Black Box Warning:

To notify prescriber of chills, fever, bruising, bleeding

• 
Not to use any prescription, OTC products, herbs without approval of prescriber; products with aspirin, NSAIDs may cause bleeding

• 
To notify all health care providers of product use

• 
That product can be taken without regard to meals

• 
That it may take longer for bleeding to stop

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

ticarcillin/clavulanate (Rx)

Timentin

Func. class.:
Broad-spectrum antiinfective

Chem. class.:
Extended-spectrum penicillin, β-lactamase inhibitor

ACTION:

Interferes with cell-wall replication of susceptible organisms; osmotically unstable cell wall swells, bursts from osmotic pressure; clavulanate inhibits β-lactamase and protects against enzymatic degradation of ticarcillin

USES:

Respiratory, soft-tissue, and urinary tract infections; bacterial septicemia; effective for gram-positive cocci
(Staphylococcus aureus, Streptococcus faecalis, Streptococcus pneumoniae)
, gram-negative cocci
(Neisseria gonorrhoeae)
, gram-positive bacilli
(Clostridium perfringens, Clostridium tetani)
, gram-negative bacilli
(Bacteroides, Fusobacterium nucleatum, Escherichia coli, Proteus mirabilis, Salmonella, Morganella morganii, Proteus rettgeri, Enterobacter, Pseudomonas aeruginosa, Serratia);
and
Peptococcus, Peptostreptococcus
, and
Eubacterium

CONTRAINDICATIONS:

Neonates, hypersensitivity to penicillins

Precautions:
Pregnancy (B), hypersensitivity to cephalosporins, renal disease

DOSAGE AND ROUTES
Calculator
Systemic/urinary tract infections, moderate/severe infections

• Adult ≥60 kg:
IV INF
3.1 g q4-6hr

• Adult <60 kg:
IV INF
200-300 mg/kg/day q4-6hr

• Child >60 kg:
IV INF
3.1 g q4-6hr

• Child <60 kg:
IV INF
300 mg/kg/day q4hr

• Full-term neonates/infants <3 mo (unlabeled):
IV
50 mg/kg q4hr for severe infections;
IV
50 mg/kg q6hr for mild to moderate infections

Mild to moderate infections

• Child ≥60 kg:
IV INF
3.1 g q6hr

• Child <60 kg:
IV INF
200 mg/kg/day q6hr

Renal dose

• Adult:
IV INF
loading dose 3.1 g; CCr 60 ml/min, 3.1 g q4hr; CCr 30-60 ml/min, 2 g q4hr; CCr 10-30 ml/min, 2 g q8hr; CCr <10 ml/min, 2 g q12hr; CCr <10 ml/min with hepatic dysfunction, 2 g q24hr

Available forms:
Inj 3 g ticarcillin, 0.1 g clavulanate; IV inf 3 g ticarcillin, 0.1 g clavulanate; powder for inj 3 g ticarcillin, 0.1 g clavulanate

Administer:

• 
Product after C&S, give ≥q1hr before bactericidal anti-infectives, change IV site q48hr

Intermittent IV INF route

• 
After diluting ≤3.1 g/13 ml of sterile water or NaCl (200 mg/ml), shake; may further dilute in ≥50-100 ml NS, D
5
W, or LR sol and run over 1/2 hr

Y-site compatibilities:
Allopurinol, amifostine, amikacin, anidulafungin, atropine, aztreonam, bivalirudin, bumetanide, ceFAZolin, cefepime, cefotaxime, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, cimetidine, clindamycin, cyclophosphamide, cycloSPORINE, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxel, DOPamine, DOXOrubicin liposome, doxycycline, enalaprilat, EPINEPHrine, esmolol, etoposide phosphate, famotidine, fenoldopam, filgrastim, fluconazole, furosemide, gemcitabine, gentamicin, granisetron, heparin, hydrocortisone, HYDROmorphone, imipenem/cilastatin, insulin, isoproterenol, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, melphalan, meperidine, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, milrinone, morphine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, palonosetron, pantoprazole, PEMEtrexed, penicillin G potassium, perphenazine, phenylephrine, procainamide, propofol, propranolol, ranitidine, remifentanil, sargramostim, sodium bicarbonate, tacrolimus, teniposide, theophylline, thiotepa, tirofiban, tobramycin, vasopressin, verapamil, vinorelbine, voriconazole

SIDE EFFECTS

CNS:
Anxiety,
seizures,
confusion, drowsiness

GI:
Nausea, vomiting, diarrhea;
increased AST, ALT; abdominal pain, glossitis, colitis,
pseudomembranous colitis, hepatotoxicity

HEMA:
Anemia, increased bleeding time,
bone marrow depression, granulocytopenia

INTEG:
Rash, urticaria,
toxic epidermal necrolysis,
pain at injection site

META:
Hypokalemia, hypernatremia

SYST:
Anaphylaxis, Stevens-Johnson syndrome,
overgrowth of organisms

PHARMACOKINETICS

IV:
Peak 30-45 min, duration 4 hr, half-life 64-68 min, excreted in urine

INTERACTIONS

 
Increase:
bleeding—anticoagulants

Increase:
methotrexate level—methotrexate, uric acid, bilirubicin, BUN, creatining, alk, phos, LDH

Increase:
ticarcillin concentrations—probenecid, sulfipyrazone

Decrease:
antimicrobial effect of ticarcillin—tetracyclines, aminoglycosides IV, chloramphenicol, macrolides, sulfonamides

Decrease:
effect—
oral contraceptives,
erythromycin

Drug/Lab Test

False positive:
urine glucose, urine protein, Coombs’ test

Increase:
LFTs, sodium, eosinophils, INR bleeding time

Decrease:
Hgb, potassium, platelets, WBC, granulocytes

NURSING CONSIDERATIONS
Assess:

• 
Infection: WBC, wound, temperature, sputum, urine, baseline and periodically

 
Pseudomembranous colitis:
diarrhea, abdominal pain, fever, fatigue, anorexia; possible anemia, elevated WBC count, low serum albumin; stop product; usually either vancomycin or IV metroNIDAZOLE is given

 
Serious skin reactions:
Stevens-Johnson syndrome, toxic epidermal necrolysis; anaphylaxis: wheezing, rash, laryngeal edema; have emergency equipment nearby

• 
Hepatic studies: AST, ALT

• 
Blood studies: WBC, RBC, Hct, Hgb, bleeding time, platelets, baseline and periodically

• 
Renal studies: BUN, creatinine, sodium, potassium

• 
Bowel pattern before, during treatment

• 
Skin eruptions after administration of penicillin to 1 wk after discontinuing product

Perform/provide:

• 
EPINEPHrine, suction, tracheostomy set, endotracheal intubation equipment

• 
Storage of reconstituted sol 12-24 hr at room temp, or 3-7 days refrigerated

Evaluate:

• 
Therapeutic response: Resolution of infection

Teach patient/family:

• 
To report persistent diarrhea with blood, pus, mucous, or fever

• 
That culture may be taken after completed course of medication

• 
To report sore throat, fever, fatigue (may indicate superinfection); CNS effects (anxiety, depression, hallucinations, seizures)

• 
To wear or carry emergency ID if allergic to penicillins

• 
To use alternative birth control method instead of hormonal

TREATMENT OF OVERDOSE:

Withdraw product, maintain airway, administer EPINEPHrine, O
2
, IV corticosteroids for anaphylaxis

Other books

Stolen-Kindle1 by Gemus, Merrill
Grist Mill Road by Christopher J. Yates
One Touch More by Mandy Baxter
Hot Whisper by Luann McLane